IntelGenx Announces Co-Development And Commercialization Of Cannabinoid-Infused VersaFilm Products With Tilray
Portfolio Pulse from Benzinga Newsdesk
IntelGenx Corp. and Tilray Brands Inc. have entered into a second amendment to their November 2018 license, development and supply agreement for the co-development and commercialization of cannabinoid-infused VersaFilm products. The amendment settles IntelGenx's arbitration claim against Tilray and includes an initial purchase order from Tilray for three SKUs. The agreement also allows for IntelGenx's co-development and commercialization of CBD, THC, and combination THC:CBD products with additional partners, and removes any royalties paid to or from Tilray.
November 06, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IntelGenx's partnership with Tilray for the co-development and commercialization of cannabinoid-infused VersaFilm products has been strengthened with a new amendment. This could potentially increase IntelGenx's revenues and market presence.
The amendment to the agreement with Tilray includes an initial purchase order, which will directly contribute to IntelGenx's revenues. The ability to co-develop and commercialize products with additional partners could also expand IntelGenx's market presence and future revenue streams.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Tilray's partnership with IntelGenx for the co-development and commercialization of cannabinoid-infused VersaFilm products has been strengthened with a new amendment. This could potentially increase Tilray's product offerings and market presence.
The amendment to the agreement with IntelGenx includes an initial purchase order, which will directly contribute to Tilray's product offerings. The ability to co-develop and commercialize products with additional partners could also expand Tilray's market presence and future revenue streams.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100